Results 151 to 160 of about 6,459 (257)

Weight‐Lowering Drugs and Natural Female Fertility—A Systematic Review and Meta‐Analysis

Clinical Obesity, Volume 16, Issue 4, August 2026.
ABSTRACT Overweight and obesity are global health concerns linked to impaired female fertility. Weight‐lowering drugs are an alternative for achieving weight loss; however, their effect on natural female fertility is unclear. A systematic review and meta‐analysis were conducted to summarise the literature on the effects of weight‐lowering drugs on ...
Shaikha Jabor Alnaimi, Dana Muwafag Alsugeir, Li Wei, Kirsten Harvey, Ruth Brauer   +4 more
wiley   +1 more source

Evaluating the Therapeutic Potential of Tirzepatide in Liver Diseases: A Comprehensive Review

Objective: This review examines tirzepatide, a GLP-1 agonist, to treat liver diseases like nonalcoholic fatty liver disease (NAFLD) and metabolic-associated steatohepatitis (MASH).
Bryan, Carina, Kahook, Zaneh, Parmar, Mayur S, Jones, Talaya   +3 more
core   +1 more source

Tirzepatide and Cardiometabolic Effects in Obese Non-diabetic Adults: A Systematic Review, Meta-Analysis, and Narrative Synthesis of Cardiovascular Outcomes. [PDF]

Cureus
Chaparala P, Aravind Rongali D, Khot M, Rangachari B, Ahmed KU, Suri S, Greeshma M, Shafiq MM.   +7 more
europepmc   +1 more source

A Service Evaluation of a Specialist Multi‐Disciplinary Weight Management Service Based in Primary Care Including Long‐Term Follow‐Up Data

Clinical Obesity, Volume 16, Issue 4, August 2026.
ABSTRACT This service evaluation of a primary care‐based specialist weight management service reports data from 1094 patients over 5 years (2014–2019), including weight data at 1‐year post‐discharge. The results show clinically and statistically significant improvements in weight, diet, physical activity, quality of life, blood pressure and blood ...
Helen M. Parretti, Carly A. Hughes, Sally Erskine, Nicholas Steel, Amy Jennings   +4 more
wiley   +1 more source

Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7073-7082, August 2026.
ABSTRACT Aim This study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections. Materials and Methods In this multicentre, randomised, placebo‐controlled and semaglutide‐positive‐
Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan   +9 more
wiley   +1 more source

Pityriasis Lichenoides et Varioliformis Acuta Associated With Tirzepatide: A First Report. [PDF]

J Diabetes
Deniz MS, Sarac GA, Celik B, Kaya M, Balta H, Kecik M, Topaloglu O, Ersoy R, Cakir B.   +8 more
europepmc   +1 more source

Effect of Tirzepatide on Health‐Related Quality of Life in Japanese Patients With Obesity Disease: Patient‐Reported Outcomes From the SURMOUNT‐J Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6639-6648, August 2026.
ABSTRACT Aims We evaluated the impact of tirzepatide on health‐related quality of life (HR‐QoL) in Japanese individuals with obesity disease from the phase 3 SURMOUNT‐J trial. Materials and Methods Japanese adults with obesity disease without diabetes were randomized 1:1:1 to tirzepatide (10 or 15 mg) or placebo for 72 weeks as an adjunct to lifestyle ...
Hiroaki Masuzaki, Hirotaka Nagashima, Tomotaka Shingaki, Tomonori Oura, Ichiro Tatsuno   +4 more
wiley   +1 more source

Tirzepatide – new treatment option for patient with type 2 diabetes [PDF]

Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Chişinău, Republica MoldovaIntroduction. Type II diabetes is a global problem of the 21st century.
Mufeed, Majeed
core  

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6595-6606, August 2026.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source

Clinical impact of tirzepatide on patients with chronic obstructive pulmonary disease. [PDF]

Front Pharmacol
Wu JY, Lin YM, Hsu WH, Liu TH, Tsai YW, Huang PY, Chuang MH, Lai CC.   +7 more
europepmc   +1 more source